Answers are grounded in this paper and cite their sources.
Objective Analyze recovery metrics and safety of rechallenge after neurological immune-related adverse events from immune checkpoint inhibitor use. Background Immune checkpoint inhibitors (ICIs) are a foundational therapy in immunogenic solid tumors. Neurological immune-related adverse events (nIRAE) from ICI therapy often impact survival and treatment approaches. More data is needed on longitudinal outcomes and the safety of rechallenge in ICI-related nIRAE, especially in patients with minimal residual disability. Design/Methods We retrospectively reviewed 49 cancer patients who developed ICI-related nIRAE at Moffitt Cancer Center between 2018-2025. Data collected included cancer subtype, ICI class used, nIRAE phenotype, time from ICI initiation to nIRAE onset, survival time after nIRAE, modified Rankin Scale (mRS) at nadir, mRS at 6 months post-nIRAE, and outcomes of any ICI rechallenge. Results Cancer subtypes included melanoma (N=28), lung (N=12), and renal (N=9). ICI classes included PD-1 (43%), PD-1/CTLA-4 (43%), PD-L1 (8%), and PD-1/LAG-3 (6%). Mean time from ICI initiation to nIRAE onset was 4.6 ± 2.2 months. Mean survival time after nIRAE was 16.6 ± 4.2 months. nIRAE phenotypes included neuropathy (N=22), myositis (N=17), encephalitis (N=10), myasthenia gravis (N=5), demyelinating (N=2), and vasculitis (N=1). Mean mRS at nadir was 3.6 ± 0.4. Mean mRS after 6 months was significantly lower at 2.7 ± 0.6 (p=0.013). 48% of patients had minimal to no disability after 6 months (mRS ≤ 1). ICI was rechallenged in 5 patients in our cohort (4 melanoma and 1 renal, all with neuropathy and mRS at 6 months post-nIRAE of 1). None of these patients experienced nIRAE recurrence. Conclusions ICI-related nIRAE demonstrated significant functional improvement in our cohort after 6 months, with 48% of cases achieving minimal to no disability. In a subset of patients with the neuropathy phenotype and good functional status, ICI rechallenge was well-tolerated with no recurrence of nIRAE, supporting a patient-centered, individualized approach in select cases.
No takes yet. Share an insight, caveat, or question.
Jaffer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: